Suppr超能文献

来自AQUA注册研究的见解:美国抗胆碱能药物联合使用情况的回顾性研究。

Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States.

作者信息

Cooperberg Matthew R, Mbassa Rachel, Walker David, Meeks William, Lockefeer Amy, Jiang Baoguo, Li Tina, Johnston Karissa, Fang Raymond

机构信息

Departments of Urology and Epidemiology & Biostatistics, University of California, San Francisco, CA, USA.

American Urological Association, Linthicum, MD, USA.

出版信息

Ther Adv Urol. 2023 Jan 19;15:17562872221150572. doi: 10.1177/17562872221150572. eCollection 2023 Jan-Dec.

Abstract

BACKGROUND

Anticholinergic (ACH) burden is a risk factor for negative health outcomes among older adults. Several medications contribute to ACH burden, including antimuscarinics used to manage overactive bladder (OAB).

OBJECTIVES

This study aimed to understand the extent of ACH burden in an OAB population in the United States.

DESIGN

Non-interventional retrospective analysis.

METHODS

Adults with OAB whose care providers participated in the American Urological Association Quality (AQUA) Registry between 2014 and 2020 were included in this study. An adapted version of the Pharmacy Quality Alliance (PQA) measure of anticholinergic polypharmacy (poly-ACH) was used to assess ACH burden. The primary outcome was the annual prevalence of poly-ACH, and a secondary outcome was the percentage of patients taking 0, 1, 2, 3, 4, or ⩾ 5 ACH medications by calendar year. Analyses were stratified by age category at diagnosis and sex.

RESULTS

The sample comprised 552,840 patients with OAB. The mean age at initial OAB diagnosis was 65.7 years (58.2% male; 57.4% white). Prevalence of poly-ACH was highest in 2015 (3.7%) and lowest in 2020 (1.9%). Patients prescribed no ACH medications made up the largest proportion of each cohort, while those prescribed five or more comprised the smallest. The trend of decreasing proportions of patients taking increasing numbers of ACH medications was consistent. The proportion of patients prescribed no ACH medications increased from 63.3% in 2014 to 74.6% in 2020. The percentage of those prescribed three or more ACHs remained largely unchanged. Poly-ACH was highest among younger individuals (< 65 years of age) and females; temporal trends were similar overall and within each age and sex stratum.

CONCLUSION

In this study, poly-ACH in patients with OAB was relatively infrequent and decreased over the study period. Further evaluation of poly-ACH is needed to assess whether the study findings reflect increased awareness of the negative effects of poly-ACH.

摘要

背景

抗胆碱能负担是老年人健康不良后果的一个风险因素。多种药物会导致抗胆碱能负担,包括用于治疗膀胱过度活动症(OAB)的抗毒蕈碱药物。

目的

本研究旨在了解美国OAB人群中抗胆碱能负担的程度。

设计

非干预性回顾性分析。

方法

本研究纳入了2014年至2020年间其护理提供者参与美国泌尿外科学会质量(AQUA)登记系统的OAB成年患者。采用药房质量联盟(PQA)抗胆碱能多药治疗(多抗胆碱能)测量方法的一个改编版本来评估抗胆碱能负担。主要结局是多抗胆碱能的年度患病率,次要结局是按日历年服用0、1、2、3、4或⩾5种抗胆碱能药物的患者百分比。分析按诊断时的年龄类别和性别进行分层。

结果

样本包括552,840例OAB患者。初次诊断OAB时的平均年龄为65.7岁(男性占58.2%;白人占57.4%)。多抗胆碱能的患病率在2015年最高(3.7%),在2020年最低(1.9%)。未开具抗胆碱能药物的患者在每个队列中占比最大,而开具五种或更多抗胆碱能药物的患者占比最小。服用抗胆碱能药物数量增加的患者比例下降的趋势是一致 的。未开具抗胆碱能药物的患者比例从2014年的63.3%增至2020年的74.6%。开具三种或更多抗胆碱能药物的患者百分比基本保持不变。多抗胆碱能在较年轻个体(<65岁)和女性中最高;总体以及在每个年龄和性别分层中的时间趋势相似。

结论

在本研究中,OAB患者中的多抗胆碱能情况相对不常见,且在研究期间有所下降。需要对抗胆碱能负担进行进一步评估,以确定研究结果是否反映了对抗胆碱能负担负面影响的认识提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc7b/9871979/220a4c2b88fa/10.1177_17562872221150572-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验